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Abstract
Background: The number of inducible adhesion mole-
cules known to be involved in cell-mediated allograft
rejection is still increasing. In addition, recent data de-
scribe complement activation during acute humoral allo-
graft rejection. The aim of this study was to assess
whether specific molecules from either pathway are ex-
creted into urine and whether they can provide useful
diagnostic tools for the monitoring of renal transplant
recipients. Methods: Urinary concentrations of soluble
adhesion molecules (sICAM-1, sVCAM-1) and of the
complement degradation product C4d were determined
by standardized ELISA technique in 75 recipients of renal
allografts and 29 healthy controls. Patient samples were
assigned to four categories according to clinical criteria:
group 1: acute steroid-sensitive rejection (ASSR, n = 14),
group 2: acute steroid-resistant rejection (ASRR, n = 12),
group 3: chronic allograft dysfunction (CAD, n = 20) and
group 4: stable graft function (SGF, n = 29). Results: All
patients with rejection episodes (groups 1–3) had signifi-
cantly higher values of urinary sC4d compared with
healthy controls and patients with stable graft function
(p ! 0.05). The urinary levels of sVCAM-1 were signifi-
cantly higher in group 2 (ASRR) compared with all other
groups (p ! 0.001). Uniformly low amounts of s-VCAM-1
and complement-split product C4d were excreted by
healthy controls (group 0). In contrast, urinary sICAM-1
concentration in healthy controls was almost as high as
in group 2 (ASRR) whereas patients with a stable func-
tioning graft (group 4) excreted significantly less sICAM-
1 (p ! 0.05). Conclusion: The evaluation of sVCAM-1 and
sC4d excretion in urine can provide a valuable tool with
regard to the severity and type of allograft rejection. With
respect to long-term allograft survival, serial measure-
ments of these markers should have the potential to
detect rejection episodes and prompt immediate treat-
ment.
Copyright © 2003 S. Karger AG, Basel
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Introduction
Inducible adhesion molecules are well-recognized
players in cell-mediated allograft rejection. There is accu-
mulating evidence that specific binding of T-lymphocyte
receptors to antigen as well as adhesive and invasive inter-
actions between circulating leukocytes and vascular endo-
thelial cells during non-specific inflammatory reactions
are operative during allograft rejection [1]. With respect
to this, intercellular adhesion molecule-1 (ICAM-1,
CD54) and vascular cell adhesion molecule-1 (VCAM-1,
CD106) have attracted special interest.
ICAM-1, a 76- to 114-kDa type I transmembrane mole-
cule (507 amino acids), is the major ligand for CD11a/
CD18 (LFA-1) on leukocytes and CD11b/CD18 (Mac-1)
on monocytes and granulocytes. ICAM-1 mediates leuko-
cyte migration and adhesion to target structures by binding
to LFA-1 and Mac-1 [2]. Although these receptors are only
expressed on leukocytes, ICAM-1 can be expressed weakly
on resting endothelium by lymphocytes and some other leu-
kocytes. The expression on other cell types such as mesan-
gial cells and epithelial cells is rapidly increased in vitro
upon stimulation by cytokines [3]. Four hours after stimu-
lation ICAM-1 is initially expressed on the cell surface,
reaches a peak level expression after 24 h and is sustained
for at least 72 h [4]. Its expression is increased on capillary
endothelium during acute and chronic allograft rejection,
and de novo synthesis in tubular epithelial cells has been
reported correlating with the severity of rejection [5–7].
VCAM-1 is a 110-kDa glycoprotein of the immuno-
globulin superfamily which is absent on resting endothe-
lium. It is one of the major ligands for the very late antigen-4
(VLA-4) on T lymphocytes [8] and supports adhesion of
eosinophils, basophils, monocytes and lymphocytes, but
not neutrophils. In contrast to ICAM-1, VCAM-1 is mini-
mally expressed in normal kidneys, but is up-regulated in
transplanted allografts. It is highly expressed on capillary
endothelium in areas of mononuclear cell infiltration in
human cardiac, pancreatic and liver allograft rejection [9–
11]. During renal allograft rejection, up-regulated expres-
sion of VCAM-1 on both renal tubular and peritubular vas-
cular endothelial cells has been demonstrated [12, 13].
Usually prominent induction of VCAM-1 is observed on
the endothelium of peritubular capillaries, venules and
arterioles in areas of leukocyte infiltration [14].
In acute humoral allograft rejection, several studies
have recently re-introduced the complement system [15].
Complement activation within the graft might potentiate
antibody-mediated graft injury. Deposition of the com-
plement-split product C4d along peritubular capillaries
has been suggested to be a valuable marker for activation
of the antibody-dependent classical pathway in humoral
rejection. Furthermore, the incidence of capillary C4d
was associated with accelerated graft loss [16, 17]. C4d in
PTC walls was reported to be more specific and sensitive
than traditional criteria in distinguishing acute humoral
from acute cellular rejection [18]. A recent study impli-
cated deposition of C4d in peritubular capillaries with
development of chronic humoral graft rejection [19].
The aim of our study was to assess to what amount
specific adhesion molecules and the complement-split
product C4d derived from the classical pathway are
excreted into urine during renal allograft rejection. This
would add a non-invasive method to the diagnostic arma-
ment of renal allograft dysfunction.
Patients and Methods
Patients
This study included 75 recipients of cadaveric renal allografts
(mean age 49.5 B SD 10.6 years). Patients received a standard
immunosuppressive regime consisting of ciclosporine, azathioprine
and prednisolone. By the time of urine sampling, kidney transplanta-
tion dated back for an average of 65.4 months (B SD 43.4; range
1–204). All patients with signs of bacterial or viral infections were
excluded from the study. Thus only those patients with normal val-
ues for C-reactive protein (!50.0 mg/l) and negative serologic tests
for CMV, EBV and HHV-6 were considered. All patients had been
transplanted at the Department of Transplant Surgery, Klinikum
Grosshadern, University of Munich, Germany.
In order to prove the clinical relevance of differences in urinary
excretion, patients were subdivided into four categories according to
the severity of graft rejection classified primarily by clinical criteria.
26 patients undergoing acute rejection episodes were treated with
prednisolone (250 mg i.v. daily for 3 consecutive days) and/or anti-
lymphocyte antibodies. Thus, 14 patients with reversible creatinine
increases were classified as steroid-sensitive acute rejection (group
1). 12 patients showing no reaction to steroids were classified to
group 2 (steroid-resistant acute rejection). Acute rejections (ASSR
and ASRR) were observed within the first year after transplantation.
20 patients with ongoing, biopsy confirmed chronic kidney allograft
dysfunction (CAD) were classified as group 3. Urine samples of
this group were obtained between 12 and 204 months after trans-
plantation. Serum creatinine in this subgroup was 62.5 mg/dl
(191.3 Ìmol/l). The remaining 29 patients with stable graft function,
defined as change in serum creatinine !0.2 mg/dl (15.3 Ìmol/l) with-
in the last 2 months, were assigned to group 4.
Healthy Controls
29 subjects without clinical or laboratory signs of kidney disease
(group 0) served as normal controls (mean age 27 B SD 13 years).
Urine Samples
Urine samples from patients with clinical suspicion of acute
rejection episodes were collected in a range of 0–5 days before antire-
jection therapy was started. Samples from all other patients were
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Fig. 1. Urinary excretion of sVCAM-1 of healthy controls and
renal transplant recipients with stable graft function (SGF) and
recipients with rejection episodes (ASSR, acute steroid-sensi-
tive rejection; ASRR, acute steroid-resistant rejection; CAD
chronic allograft dysfunction). p values: 0 vs. 1, 0 vs. 2, 0 vs. 3, 2
vs. 4 (!0.0001); 1 vs. 2, 2 vs. 3 (0.001); 3 vs. 4 (0.05).
tested every 6 months. In the case of worsening graft function and
histologic signs of chronic allograft dysfunction, we collected urine
on the day of biopsy. 10 ml of urine, taken as a second morning sam-
ple, was centrifuged for 10 min at 2,000 min–1 at 8°C. After determi-
nation of urinary creatinine and total urine protein in supernatant,
the urine was stored at –20°C until sICAM-1, sVCAM-1 and sC4d
concentrations were tested by an ELISA technique.
ELISAs
Commercially available ELISA kits were used to determine uri-
nary concentrations of soluble adhesion molecules sICAM-1 (Serva,
Heidelberg, Germany), sVCAM-1 (Hermann Biermann, Bad Nau-
heim, Germany) and of complement-split product sC4d (Quidel, San
Diego, Calif., USA). The C4d fragment enzyme immunoassay mea-
sures the amount of C4d-containing activation fragments of C4 (C4b,
iC4b and C4d) present in human plasma or serum specimens. The
limit of detection of C4d ELISA is 0.007 Ìg/ml.
All samples were tested in duplicate by a standardized ELISA
technique. For sICAM-1 and sC4d ELISA, undiluted urine was used.
sVCAM-1 assays were performed with 1:10 diluted urine. Extinc-
tions were measured at 405 nm (against the blank) and documented
by a computerized ELISA reader (Multiscan Plus MKII, Flow Labo-
ratories, Meckenheim, Germany).
Statistical Analysis
Data were expressed as mean B SEM. Urine samples were
grouped by clinical diagnosis. In order to test for significant differ-
ences in urinary adhesion molecule and complement component
C4d levels between the groups, analysis of variance was performed. A
p value of !0.05 was considered to be significant. Possible correla-
tions between serum creatinine, total urine protein and the levels of
adhesion molecules and C4d in urine were analyzed by linear regres-
sion. For data management and computations, the BMDP statistical
software (BioMeDical Programs, Cork, Ireland) was used.
Results
sVCAM-1
Patients with acute steroid-resistant rejection (group 2)
excreted urinary sVCAM-1 at a significantly higher level
(282.94 B 35.91 ng/ml; p ! 0.001) than all other groups
(fig. 1). The lowest amounts of sVCAM-1 (7 times less)
were excreted by healthy controls (group 0, 39.47 B
1.18 ng/ml) reaching statistical significance compared to
groups 1, 2 and 3 (p ! 0.0001). Measurements of urinary
sVCAM-1 concentrations in patients with ASSR (group 1,
95.74 B 13.97 ng/ml) and those with CAD (group 3,
108.24 B 12.27 ng/ml) resembled each other. Patients
with stable graft function (group 4) showed a lower
sVCAM-1 excretion (71.32 B 10.29 ng/ml).
sC4d
As shown in figure 2, urinary excretion of sC4d was
similar to that of sVCAM-1, albeit at a lower quantitative
level. Again, patients with acute steroid-resistant rejection
(group 2) showed highest levels of urinary sC4d (72.72 B
18.49 ng/ml) reaching significance compared to group 0
(healthy controls) and group 4 (stable graft function; p !
0.001) but not to the other groups. Patients with chronic
allograft dysfunction (group 3; 54.20 B 17.98 ng/ml) and
patients with acute steroid-sensitive rejection (group 1;
31.38 B 7.85 ng/ml) displayed significant differences in
urinary C4d excretion compared to group 0 (healthy con-
trols) and group 4 (stable graft function; p ! 0.0001 and
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Fig. 2. Urinary excretion of sC4d of healthy controls and renal
transplant recipients with stable graft function (SGF) and re-
cipients with rejection episodes (ASSR, acute steroid-sensi-
tive rejection; ASRR, acute steroid-resistant rejection; CAD,
chronic allograft dysfunction). p values: 0 vs. 2, 0 vs. 3, 2 vs. 4, 3
vs. 4 (0.0001); 1 vs. 4 (0.01); 0 vs. 1 (0.05).
Fig. 3. Urinary excretion of sICAM-1 of healthy controls and
renal transplant recipients with stable graft function (SGF) and
recipients with rejection episodes (ASSR, acute steroid-sensi-
tive rejection; ASRR, acute steroid-resistant rejection; CAD,
chronic allograft dysfunction). p values: 0 vs. 4 (!0.01); 2 vs. 4
(!0.05).
p ! 0.01 respectively). Patients with stable graft function
(group 4) and healthy controls (group 0) excreted low
amounts of sC4d: 9.48 B 2.90 and 5.81 B 1.16 ng/ml
(fig. 2).
sICAM-1
Surprisingly, patients with stable graft function (group
4) excreted lower levels of sICAM-1 as healthy controls
(3.74 B 0.48 vs. 6.72 B 1.04 ng/ml). Patients with rejec-
tion episodes showed the following urinary sICAM-1
excretions: group 1 (acute steroid-sensitive rejection) 4.75
B 1.01 ng/ml, group 2 (acute steroid-resistant rejection)
6.79 B 1.28 ng/ml and group 3 (chronic allograft dysfunc-
tion) 5.24 B 1.09 ng/ml. These differences reached no sta-
tistical significance. Only group 2 (ASSR) patients re-
vealed significantly higher sICAM-1 values than patients
with stable functioning renal transplants (group 4, p =
0.0153) (fig. 3). However, no statistical difference was
observed between patients with acute steroid-resistant
rejection (group 2) and normal controls (group 0).
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In order to determine the kinetics of sC4d and
sVCAM-1 concentrations in urine, serial measurements
were performed in various patients. Over a period of 3
years, we collected urine samples every 6 months. Uni-
formly elevated levels of sC4d and sVCAM-1 were ob-
served within the first half year after transplantation in all
patient groups. After 12 months, concentrations of sC4d
and sVCAM-1 in group 4 (stable graft function) fell to lev-
els comparable to normal controls. In patients with acute
rejection episodes, a rapid increase in sVCAM-1 and
sC4d excretion within the first year after transplantation
could be observed preceding a rise in serum creatinine
and the initiation of antirejection therapy for several
weeks. In the case of successful treatment the urinary con-
centrations of both molecules returned to the initial val-
ues after a time period of some months. In the CAD group
the values did not return to the initial levels.
To exclude that a raised urinary concentration of
sVCAM-1 and sC4d was merely the function of an
increased loss of this molecule, the excretion of urinary
protein and creatinine was compared with that of urinary
sVCAM-1 and sC4d in the healthy control group. By the
means of regression analysis, no correlation was found
between urinary creatinine or protein concentration and
excretion of adhesion molecule sVCAM-1 or comple-
ment-split product sC4d. Since no correlation was docu-
mented for the normal controls, we did not perform fur-
ther studies in the patient groups.
Discussion
The present study investigates the clinical relevance of
soluble adhesion molecules and complement-split prod-
uct C4d in urine for diagnosis of renal allograft rejections
and monitoring after kidney transplantation. Under most
circumstances, serum levels of adhesion molecules are
unspecific markers for ongoing immune reactions like
allograft rejection. Yet in the situation of renal transplan-
tation the determination of such molecules in urine offers
a specific tool for the detection of a state of immunologi-
cal responsiveness. Nevertheless, ongoing infections
should be excluded in order to avoid false positive
results.
We could demonstrate significant differences in uri-
nary excretion of sVCAM-1 and complement-split prod-
uct sC4d between patients with stable graft function and
those with acute and chronic rejection episodes. In con-
trast, differences between urinary sICAM-1 excretion be-
tween the four transplant groups were less distinctive.
Normal controls displayed similar sICAM-1 concentra-
tions in urine than acutely rejecting allograft recipients.
The observation that healthy controls excrete more sI-
CAM-1 than patients with stable graft function is surpris-
ing and may be an unspecific effect of immunosuppres-
sion limiting the usefulness of this parameter. sICAM-1 is
shed from ICAM-1-expressing cells, most likely by proteo-
lytic cleavage, and is released in the surrounding fluid
[20]. Increased serum sICAM-1 levels were found in
patients with acute rejections 3–4 days before diagnosis of
acute rejection [21], and high urinary levels in steroid-
resistant acute kidney allograft rejection [22]. By urine
flow cytometry, Roberti et al. [23] determined active
urine sediments whereby HLA-DR turned out to be the
most sensitive and ICAM-1 the most specific marker for
acute rejection. The presence of CD14+ cells was highly
suggestive of chronic rejection. By using urine immunocy-
tology, Chan et al. [24] could distinguish between the
heightened ICAM-1 expression on renal tubular epithelial
cells in acute rejection and the lower expression in acute
tubular necrosis. They found a strong correlation with
immunohistology and the clinical diagnosis. Further-
more, they demonstrated that tubular ICAM-1 expression
in graft biopsies was proportional to the expression on uri-
nary tubular cells.
In contrast, other studies indicated that both sICAM-1
in urine and in serum are not useful to estimate ICAM-1
expression in a transplant. Lhotta et al. [25] reported uri-
nary sICAM-1 as a marker of proteinuria that did not
reflect ICAM-1 expression on proximal tubular epithelial
cells [26]. Our similar results in all patient groups indicate
that measurement of urinary sICAM-1 is unsuitable to
determine the specific pathology and severity of allograft
rejection. This could be a result of the use of miscella-
neous ELISA kits, differing in specificity and sensitivity.
Furthermore, it is not known whether these kits distin-
guish between active or inactive material. On the other
hand, it is unclear whether molecules are altered during
excretion. In summary, the measurement of urinary
sICAM-1 appears to be imprecise because different iso-
forms of the molecule may be detected by different ELISA
kits, and the results cannot be interpreted adequately
[27].
Measuring urinary sVCAM-1 concentration, we ob-
served substantially elevated levels of this molecule in
patients with ASRR. Patients with ASSR and those with
CAD excreted sVCAM-1 at a lower but still significantly
higher level than patients with stable graft function and
normal subjects. Patients with ASSR could not be distin-
guished from those with CAD. Stable graft function was
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not associated with a significant increase in sVCAM-1
excretion as compared to normal controls. Thus the high-
ly significant differences in urinary sVCAM-1 concentra-
tions between patients with acute ASRR, CAD and stable
graft function were predictive for the type and severity of
allograft rejection. A single previous study detecting
VCAM-1 in urine reported a correlation between urinary
sVCAM-1 and up-regulation of VCAM-1 expression at
vascular and non-vascular sites [28]. Although the expres-
sion of VCAM-1 in renal kidney biopsies was found to be
raised during allograft rejection [29–31], no consistent
data exist concerning serum levels of this molecule during
allograft rejection. Several studies have reported elevated
levels of cVCAM-1 in patients with acute and/or chronic
renal allograft rejection [32], but contradictory results
failed to confirm these data [21, 33, 34]. In summary,
serum concentration measurements of cVCAM-1 add lit-
tle to the monitoring of kidney allograft rejection epi-
sodes.
Deposition of complement-split product C4d in peritu-
bular capillary (PTC) walls was strongly associated with
inferior kidney allograft outcome [17, 35]. Being more
specific and sensitive than traditional criteria [18, 19, 36],
it has been suggested that C4d is a valuable marker for
acute and chronic humoral rejection. The de novo pro-
duction of donor-specific antibodies (DSA), another clini-
copathological factor carrying a poor prognosis, was de-
tected in one third of biopsies in which C4d was present
[17, 36].
Our results demonstrated strongly elevated levels of
sC4d in urine of patients with ASRR and CAD. Nonethe-
less, because of relatively high standard errors, no clear
distinction between these two subgroups could be made.
To a lesser, but still significant extent, levels of sC4d in
urine were elevated in ASSR as compared to patients with
stable graft function and healthy controls.
Vallhonrat et al. [37] identified C4d and the pore-
forming, cytolytically inactive, fluid-phase SC5b-9 com-
plex (terminal pathway) in plasma of human heart allo-
graft recipients. No correlation between plasma levels of
complement-split products and biopsy-proven acute re-
jection or accelerated graft atherosclerosis was found.
Levels were significantly elevated in the immediate post-
transplantation period followed by a sharp decrease dur-
ing the first 4–6 weeks after transplantation. Determina-
tion of C5b-9 in urine and plasma of patients after renal
transplantation resulted in no correlation with regard to
the severity of graft rejection [38]. Measurements of C5a
(the most stable anaphylatoxin) in kidney transplant re-
cipients showed a strong correlation of this urinary com-
plement component and the occurrence of acute rejection
episodes. More interestingly, the urinary C5a elevation
preceded the clinical diagnosis by 1–2 days [38, 39].
In conclusion, renal ASRR is characterized by mas-
sively elevated levels of sVCAM-1 and the complement-
split product sC4d in urine. In our view, the high urinary
sC4d levels in ASRR episodes and in CAD point to a
humoral component in the pathogenesis of this rejection
type. This might explain the insufficient efficacy of con-
ventional immunosuppressive treatment and the high
proportion of graft losses in this subgroup of kidney allo-
graft rejections [37, 40, 41]. Preliminary data exist con-
cerning the effect of plasmapheresis in combination with
tacrolimus-mycophenolate mofetil rescue therapy or the
use of intravenous immune globulin application to sup-
press alloantibody production and modulate immune re-
sponses. Serum creatinine levels and circulating DSA
could be diminished to almost pretransplant levels [42,
43]. Protein A immunoadsorption may eventually be a
more advanced technique than plasmapheresis for thera-
py of C4d-positive acute humoral rejection. In two small
series this possible treatment modality for AHR resulted
in the restoration of excellent renal allograft function over
a prolonged time period [44, 45]. Tacrolimus-mycophe-
nolate mofetil treatment of patients with chronic humoral
rejection has also provided evidence for a sustained
decrease of DSA and reduction of covalent bound C4d in
PTC over a 12-month time period [46].
There is an absolute need for non-invasive screening
tests which monitor allograft dysfunction and are highly
sensitive, reliable and safe. Measurements of immunolog-
ical activity in serum or plasma do not reflect the situation
in the transplanted organs themselves [26, 33, 34, 38].
Our data indicate that the determination of sVCAM-1
and sC4d in urine might provide a valuable method to
determine the severity and type of renal allograft rejec-
tion. Investigation of these molecules with respect to long-
term allograft survival represents a simple, inexpensive
and non-invasive method for the routine clinical monitor-
ing after kidney transplantation.
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